A European survey of oncology nurse breakthrough cancer pain practices.

Eur J Oncol Nurs

Division of Emergencies and Critical Care, Department of Research and Development, Ullevål, Oslo University Hospital, Oslo, Norway.

Published: February 2013

Purpose Of The Research: Breakthrough cancer pain (BTCP) is a prevalent type of pain in which the nurse can play an important role in improving patients' pain symptoms and overall well-being. Nurses' experience with BTCP (number of patients, and estimates of severity and frequency), the treatment of BTCP (pharmacological and nonpharmacological treatments normally used), ratings of the importance of treatment factors, and reasons given for not advising patients to take strong painkillers are presented in the present paper.

Methods And Sample: Nurses from 12 European countries, who cared for patients with cancer, took part in a survey. In total 1618 nurses were recruited and 1241 completed the survey questionnaire.

Key Results: Almost 90% of the nurses were female, and 50.4% had >9 years of experience in oncology nursing. The majority of the nurses (47%) said that a patient typically suffered from BTCP 2-3 times a day, and the severity of the pain for the patients was described as severe by 75.5%. In all, 38.4% of the nurses were unaware that medications specifically intended for treatment of BTCP exist, and 57% reported that oral opioids were normally prescribed for BTCP at their workplace. While 38% said they did not use nonpharmacological treatments for BTCP, the most common treatment approach was positional change (used by 76.6%). The treatment varied between the European countries.

Conclusion: Patients do not receive the appropriate medical treatment for their BTCP. Nurses need better training about BTCP in general, and BTCP assessment and management specifically.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejon.2012.05.005DOI Listing

Publication Analysis

Top Keywords

treatment btcp
12
btcp
10
breakthrough cancer
8
cancer pain
8
nonpharmacological treatments
8
treatment
6
nurses
6
pain
5
patients
5
european survey
4

Similar Publications

Objective: Chronic pain strongly affects the quality of life of patients with liver cancer pain. Safe and effective management of cancer-related pain is a worldwide challenge. Traditional Chinese medicine (TCM) has rich clinical experience in the treatment of cancer pain.

View Article and Find Full Text PDF

Objectives: Knowledge gaps in defining, diagnosing, educating health practitioners and treatment options hinder breakthrough cancer pain (BtCP) management. A systematic review revealed a lack of clarity on health professional derived definitions, management strategies and professional development for BtCP. The current study aimed to explore the perspectives of multidisciplinary health professionals by seeking to understand how they define, identify, treat and manage BtCP, barriers to management and professional development requirements.

View Article and Find Full Text PDF

Assessing Gender Differences for Non-Predictable Breakthrough Cancer Pain Phenomenon: A Secondary Analysis from IOPS-MS Study.

J Pain Res

September 2024

Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy.

Article Synopsis
  • Breakthrough cancer pain (BTcP), especially the non-predictable subtype (NP-BTcP), shows notable gender differences in intensity, frequency, and treatment needs among cancer patients.
  • A study analyzed data from the Italian Oncologic Pain Survey and found that males experienced higher rates of BTcP in the thorax area, required larger doses of therapy, and had lower overall health scores compared to females.
  • Understanding these gender differences could enhance pain management strategies for cancer patients, indicating a need for more research on the characteristics of BTcP across different demographics.
View Article and Find Full Text PDF

Background: Breakthrough cancer pain (BTcP) has a negative impact on patients' quality of life, general activities, and is related to worse clinical outcomes. Fentanyl inhalant is a hand-held combination drug-device delivery system providing rapid, multi-dose (25μg/dose) administration of fentanyl via inhalation of a thermally generated aerosol. This multicenter, randomized, placebo-controlled, multiple-crossover, double-blind study evaluated the efficacy, safety, and tolerability of fentanyl inhalant in treating BTcP in opioid-tolerant patients.

View Article and Find Full Text PDF

The study assessed sublingual fentanyl citrate (SFC) effectiveness and safety for breakthrough cancer pain (BtCP) in older patients. A multicenter, retrospective, observational study was conducted in three subgroups of cancer patients aged over 65 years with BtCP. The reports were collected by 20 oncologists across 12 hospitals.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!